KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables - Other: 2018-2024

Historic Receivables - Other for Halozyme Therapeutics (HALO) over the last 2 years, with Dec 2024 value amounting to $20.3 million.

  • Halozyme Therapeutics' Receivables - Other rose 1930.00% to $20.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $20.3 million, marking a year-over-year increase of 1930.00%. This contributed to the annual value of $20.3 million for FY2024, which is 1930.00% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Receivables - Other stood at $20.3 million for Q4 2024, which was up 1,930.00% from $1.0 million recorded in Q4 2023.
  • Over the past 5 years, Halozyme Therapeutics' Receivables - Other peaked at $69.2 million during Q3 2022, and registered a low of $1.0 million during Q4 2023.
  • For the 3-year period, Halozyme Therapeutics' Receivables - Other averaged around $24.4 million, with its median value being $20.3 million (2024).
  • Per our database at Business Quant, Halozyme Therapeutics' Receivables - Other slumped by 95.23% in 2023 and then surged by 1,930.00% in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Receivables - Other stood at $7.0 million in 2020, then reached $30.0 million in 2021, then reached $69.2 million in 2022, then slumped by 95.23% to $1.0 million in 2023, then spiked by 1,930.00% to $20.3 million in 2024.
  • Its last three reported values are $20.3 million in Q4 2024, $1.0 million for Q4 2023, and $3.3 million during Q3 2023.